Search - tctmd.com

Displaying 61 - 80 of 305

Sort: Relevancy | Date

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

News Conference News EACTS 2021

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

Michael O'Riordan

October 19, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

News Conference News TCT 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

Michael O'Riordan

October 15, 2021

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

News Conference News TCT 2021

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

Yael L. Maxwell

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

FDA Issues New Guidance on Sodium Targets for Food Industry

News Daily News

FDA Issues New Guidance on Sodium Targets for Food Industry

October 14, 2021

No Harm From Thrombolytics in SCAD Patients With STEMI

News Conference News TCT 2021

No Harm From Thrombolytics in SCAD Patients With STEMI

Michael O'Riordan

October 13, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Failed MitraClip Is Uncommon, but Bleak When It Happens

News Conference News TCT 2021

Failed MitraClip Is Uncommon, but Bleak When It Happens

Michael O'Riordan

October 08, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

Higher Dose vs Added Antihypertensive? Older Patients Face Trade-offs

News Daily News

Higher Dose vs Added Antihypertensive? Older Patients Face Trade-offs

Yael L. Maxwell

October 07, 2021

Diabetes Progression in Statin-Treated Patients: VA Data

News Daily News

Diabetes Progression in Statin-Treated Patients: VA Data

Michael O'Riordan

October 06, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.